Monthly Archives: October 2019

Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor

2019-10-14T15:57:19+00:00

Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor New funding brings total Series B raise to $75.2 million Novo Holdings led round, joined by Venrock, DROIA, Osage University Partners, Lightstone and Celgene Corporation RAD51 inhibitor CYT-0851 now being evaluated [...]

Cyteir Therapeutics Secures Additional $40.2 Million in its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor 2019-10-14T15:57:19+00:00